All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-07-25T08:07:54.000Z

Which emerging therapies are likely to shape treatment approaches for relapsed MCL?

Bookmark this article

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, Which emerging therapies are likely to shape treatment approaches for relapsed mantle cell lymphoma (MCL)?

Which emerging therapies are likely to shape treatment approaches for relapsed MCL?

In this video, Wang discusses the novel therapies emerging for MCL in the relapse setting, including the chimeric antigen receptor T-cell therapy, brexucabtagene autoleucel (KTE-X19); the Bruton’s tyrosine kinase inhibitor, pirtobrutinib; and the antibody conjugate therapy, VLS-101.

 

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox